Symphony Predictions

Trials with limitations

The below list represents drug candidates in Phase 2 clinical trails that our Symphony™ platform provides rationale for efficacy, however, our scientists and researchers have questions or concerns as noted below.

See our list of candidates we predict will achieve efficacy in Phase 2 trials.

DISEASE	DRUG	MECHANISM OF ACTION	NOVEL MECHANISM OF ACTION IN DISEASE	CLINICAL TRIAL END DATE	CLINICAL TRIAL LINK	PREDICTION PUBLISHED DATE	REASON FOR CONCERN
Systemic Sclerosis (SSc)	SHP-627	TGFB1 & PDGF Inhibitor	No	November 2022	clinicaltrials.gov	August 31, 2022	Too few patients in the clinical trial (30); also concerns about the potency and selectivity of the reported mechanism of action
Ankylosing Spondylitis	Jaktinib	JAK inhibitor	No	December 2022	clinicaltrials.gov	August 31, 2022	Tolerability given Jaktinib's broad JAK inhibition
Atopic Dermatitis	Jaktinib	JAK inhibitor-	No	December 2022	clinicaltrials.gov	August 31, 2022	Tolerability given Jaktinib's broad JAK inhibition
Lupus Nephritis	Pegcetacoplan	C3 inhibitor	Yes	December 2022	clinicaltrials.gov	August 31, 2022	Too few patients in the clinical trial (21)

SYMPHONY™

Aria’s drug discovery engine.

Drug discovery is complex. Our technology decodes complex biology in an unprecedented manner, combining the widest biomedical data landscapes available with proprietary, purpose-built artificial intelligence. Symphony™ is the only AI drug discovery platform that integrates and simultaneously analyzes unrelated heterogenous data in one process. We see the whole picture, increasing our chance of fully understanding the biology and detecting a signal others can’t see.